ETOPOPHOS® Injection Launch


H2-Pharma, LLC has entered into an agreement with CHEPLAPHARM Arzneimittel GmbH to be the exclusive U.S. distributor of ETOPOPHOS® (etoposide phosphate) for injection...

ETOPOPHOS® Injection Launch2020-09-22T12:37:36-05:00

End-to-End Order Processing


H2-Pharma Automates Order Processing End-to-End—Including Chargeback Processing and Warehouse Order Fulfillment—with TrueCommerce EDI for QuickBooks Premier..

End-to-End Order Processing2020-09-22T12:41:45-05:00

XENICAL® Capsules


H2-Pharma, LLC has re-launched XENICAL® (orlistat) 120 mg Capsules via its newly formed Branded division. This opportunity arose due to the partnership with CHEPLAPHARM Arzneimittel GmbH...

XENICAL® Capsules2020-09-22T12:45:08-05:00

Mayne Pharma, Inc.


H2-Pharma, LLC has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc. In 2015 the combined market for these products was approximately $8.3 million according to IMS Health.

Mayne Pharma, Inc.2020-09-22T12:46:26-05:00
Go to Top